Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond

Sheetal M. Kircher*, Mary Mulcahy, Aparna Kalyan, Christine B. Weldon, Julia R. Trosman, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of September 17, 2020, there were more than 6.6 million confirmed cases and 196,277 deaths. Limited data are available on outcomes of immunocompromised patients, but early published reports from China indicate that those with cancer have a 3.5 times higher risk of ICU admission, mechanical ventilation, or death than those without cancer. Because of the uncertain behavior of COVID-19, it has become imperative for practices to limit exposure to vulnerable patients. Telemedicine has been one of the cornerstones of caring for patients with cancer during the COVID-19 pandemic. This review provides an overview of reimbursement policy by public and private payers before and during the COVID-19 pandemic, describes implications in cancer care, and offers considerations for future reimbursement policy.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
Issue number13
DOIs
StatePublished - Mar 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond'. Together they form a unique fingerprint.

Cite this